PR-104

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PR-104  纯度: 97.71%

PR-104 是一种选择性缺氧激活的 DNA 交联剂,可用于多种异种肿瘤模型的研究。PR-104 作为氮芥的前体药物,可有效地转化为亲脂性较强的二硝基苯甲酰胺芥菜醇 PR-104A。

PR-104

PR-104 Chemical Structure

CAS No. : 851627-62-8

规格 价格 是否有货 数量
5 mg ¥4800 In-stock
10 mg ¥8000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

PR-104 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Covalent Screening Library
  • Anti-Lung Cancer Compound Library

生物活性

PR-104 is a selective hypoxia-activated DNA cross-linking agent and can be used for the research of multiple tumor xenograft models. PR-104, as a nitrogen mustard pre-prodrug, is converted efficiently to the more lipophilic dinitrobenzamide mustards alcohol PR-104A[1].

体外研究
(In Vitro)

PR-104 (80 μM; 1 hour; SiHa cells) shows greater suppression of radiation-induced DNA single-strand breaks under hypoxic than aerobic conditions. PR-104 (100 μM; 1 hour; SiHa cells) results in phosphorylation of Ser139 of histone H2AX (gH2AX). PR-104 (0.266 mmol/kg; 18 h; SiHa cells) shows activity against hypoxic cells after irradiation. PR-104 varies in potency between cell lines, with the lowest IC50 (0.51 μmol/L) in H460 cells and highest (7.3 μmol/L) in PC3 prostate cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

PR-104 (0.56 mmol/kg; i.v. or i.p.; 0~2 hours) makes the plasma area under the curve. PR-104 (0.23 mmol/kg; i.p.; 100 days) shows antitumor activity[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD-1nu/nu mice
Dosage: 0.56 mmol/kg (Pharmacokinetics Analysis)
Administration: I.v. or i.p.
Result: The plasma area under the curve.
Animal Model: CD1-Foxn1nu mice
Dosage: 0.23 mmol/kg
Administration: I.p.
Result: Showed antitumor activity.

Clinical Trial

分子量

579.27

Formula

C14H20BrN4O12PS

CAS 号

851627-62-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-80°C, protect from light, stored under nitrogen

溶解性数据
In Vitro: 

DMSO : 100 mg/mL (172.63 mM; Need ultrasonic)

H2O : 31.25 mg/mL (53.95 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7263 mL 8.6316 mL 17.2631 mL
5 mM 0.3453 mL 1.7263 mL 3.4526 mL
10 mM 0.1726 mL 0.8632 mL 1.7263 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months (protect from light, stored under nitrogen)。-80°C 储存时,请在 6 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 5 mg/mL (8.63 mM); Clear solution

    此方案可获得 ≥ 5 mg/mL (8.63 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 5 mg/mL (8.63 mM); Clear solution

    此方案可获得 ≥ 5 mg/mL (8.63 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Patterson AV, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007;13(13):3922-3932.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务